Abagovomab
Abagovomab is a monoclonal antibody used in the treatment of ovarian cancer
Other names[edit]
- ACA 125
- Anti-idiotype ovarian cancer vaccine
- MAb ACA 125
- Monoclonal Anti-idiotype Antibody ACA125
Indications[edit]
Abagovomab is studied as an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer
Mechanism of action[edit]
- A murine IgG1 monoclonal anti-idiotype antibody, containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125, with potential antineoplastic activity.
- With a variable antigen-binding region that acts as a surrogate antigen for CA-125, abagovomab may stimulate the host immune system to elicit humoral and cellular immune responses against CA-125-positive tumor cells, resulting in inhibition of tumor cell proliferation resulting in inhibition of tumor cell proliferation
Manufacturer[edit]
Abagovomab has been developed by the pharmaceutical company Menarini.
Clinical trials[edit]
A multicenter clinical trial, internationally known as MIMOSA is being studied. In this study, Abagovomab was administered as maintenance therapy after first line therapy with surgery and chemotherapy, as opposed to standard therapy with paclitaxel and carboplatin.
- Unfortunately, phase III of a trial looking at potential benefit of Abagavomab in patients treated with ovarian cancer showed no benefit in preventing a remission.
Ovarian cancer[edit]
Ovarian cancer is an aggressive type of cancer with significant mortality. In spite of initially successful treatment with surgery and chemotherapy, which forces back the tumour "completely", i.e. into no longer visible residues, there is a relapse of the disease (recurrence) in more than half the women affected. In this window, after surgery and chemotherapy, ‘watch and wait’ abagovomab is potentially capable of deferring or even preventing the occurrence of the relapse.
Also see[edit]
External links[edit]
- Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer
- Clinical trials
- Menarini page about abagovomab
- Clinical trial MIMOSA
| Monoclonal antibodies for tumors | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
